Report Overview

The global adult malignant glioma therapeutics market size stood at around USD 1.53 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Gliomas are the type of tumor starting at glial cells of the brain and spine are the most common types of brain tumors. According to Atlas of Genetics and Cytogenetics in Oncology and Hematology, glioma comprises of about 30% of the brain tumor's and 70% of all the malignant tumor's Glioblastoma multiforme (GBM) is the most aggressive and difficult to treat form of the disease with median survival rate of 12 months



Market Drivers and Restraints

Growing prevalence of the disease, increase in aging population, huge unmet need, poor survival rate, and lack of effective therapies for the complete cure of the disease leverages great opportunity for the players to invest in the research and development of glioma therapies

The adult malignant glioma therapeutics market share is anticipated to expand at near two digit CAGR during the forecast period attributable to supportive government and regulatory policies for the development of novel therapies, advancements in the imaging technologies resulting in early detection of the disease, and favorable reimbursement policies for the glioma products across many regions of the world

Major Adult Malignant Glioma Disease Type

The major diseases include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma and others diseases

The glioblastoma multiforme disease is expected to exhibit the fastest growth over the forecast period. According to the Case Reports in Oncology, 2018, around 200 cases were reported worldwide for glioblastoma multiforme. Consequently, this segment is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Intense research and development focus of manufacturers, the presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing the pipeline of innovative novel drugs are attributed to the high growth of the segment